Androgen deprivation therapy increases brain ageing

Plata‐Bello, Julio; Plata-Bello, Ana; Pérez-Martín, Yaiza; Fajardo, Victor; Concepción-Massip, Tomás

doi:10.18632/aging.102142

Cited by 14 publications

(20 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also a positive association was found between age and WML burden in the ADT patients, but not in the control subjects. There were no significant differences in GMV and WML between patients and controls 24 …”

Section: Resultsmentioning

confidence: 65%

“…In five of the nine studies no significant differences were found in cognitive functioning between the patients on ADT and the specific control groups 24,28,31,33,34 . Clay et al 34 .…”

Section: Resultsmentioning

confidence: 96%

“…An unknown number of patients treated with orchiectomy was included, but no difference was found in visuomotor performance between patients with or without orchiectomy 34 . Interestingly, Plata‐Bello et al 24 . did not observe differences in cognitive functioning between prostate carcinoma patients on ADT and healthy controls, but they did observe a negative relationship between ADT period and GMV using MRI in 50 prostate cancer patients treated with ADT for 6 months.…”

Section: Resultsmentioning

confidence: 98%

“…They received treatment for at least 3–6 months. Of the included studies, seven were case–control studies, 24,27–32 one performed a cross‐sectional analysis (i.e. short‐term ADT vs long‐term ADT), 33 and one study used both 34 .…”

Section: Resultsmentioning

confidence: 99%

“…Furthermore, we were interested in studies combining neuropsychological tests with modern techniques to detect abnormalities in the brain (i.e. structural, functional, metabolic) in patients with prostate cancer on ADT 19–24 …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Effect of androgen deprivation therapy on cognitive functioning in men with prostate cancer: A systematic review

et al. 2021

View full text Add to dashboard Cite

The objective of this study was to review publications assessing cognitive functioning in patients with prostate cancer treated with androgen deprivation therapy. We conducted a systematic review of the literature published in PubMed, Embase, Web of Science, Cochrane Library, and PsycINFO up to February 2020. A total of 31 studies were included. Half of the studies (n = 16) demonstrated that androgen deprivation therapy in patients with prostate carcinoma did not result in a negative effect on cognitive functioning, however, still a substantial proportion of the studies (n = 11) reported a negative effect on cognitive functioning. In four studies the results were inconclusive. In the three studies using additional functional magnetic resonance imaging, no significant effect on neuropsychological tests was found, but grey matter volume, brain activity, and brain connectivity were affected. Given the substantial number of studies showing a significant negative effect of androgen deprivation therapy on cognitive functioning, clinicians should be aware of this side effect. Furthermore, future research should focus on the further examination of brain characteristics using functional magnetic resonance imaging, since these techniques might be more sensitive in detecting brain abnormalities as a result of androgen deprivation therapy.

show abstract

Section: Resultsmentioning

confidence: 65%

“…In five of the nine studies no significant differences were found in cognitive functioning between the patients on ADT and the specific control groups 24,28,31,33,34 . Clay et al 34 .…”

Section: Resultsmentioning

confidence: 96%

Section: Resultsmentioning

confidence: 98%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Effect of androgen deprivation therapy on cognitive functioning in men with prostate cancer: A systematic review

et al. 2021

View full text Add to dashboard Cite

show abstract

Androgen‐targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer

et al. 2022

View full text Add to dashboard Cite

Background Prostate cancer and multiple neurodegenerative diseases (NDD) share an age‐associated pattern of onset. Therapy of prostate cancer is known to impact cognitive function. The objective of this study was to determine the impact of multiple classes of androgen‐targeting therapeutics (ATT) on the risk of NDD. Methods A retrospective cohort study of men aged 45 and older with prostate within the US‐based Mariner claims data set between January 1 and 27, 2021. A propensity score approach was used to minimize measured and unmeasured selection bias. Disease risk was determined using Kaplan–Meier survival analyses. Results Of the 1,798,648 men with prostate cancer, 209,722 met inclusion criteria. Mean (SD) follow‐up was 6.4 (1.8) years. In the propensity score‐matched population, exposure to ATT was associated with a minimal increase in NDD incidence (relative risk [RR], 1.07; 95% CI, 1.05–1.10; p < 0.001). However, GnRH agonists alone were associated with significantly increased NDD risk (RR, 1.47; 95% CI, 1.30–1.66; p <0.001). Abiraterone, commonly administered with GnRH agonists and low‐dose prednisone, was associated with a significantly decreased risk (RR, 0.77; 95% CI, 0.68–0.87; p < 0.001) of any NDD. Conclusions Among patients with prostate cancer, GnRH agonist exposure was associated with an increased NDD risk. Abiraterone acetate reduced the risks of Alzheimer's disease and Parkinson's disease conferred by GnRH agonists, whereas the risk for ALS was reduced by androgen receptor inhibitors. Outcomes of these analyses contribute to addressing controversies in the field and indicate that GnRH agonism may be a predictable instigator of risk for NDD with opportunities for risk mitigation in combination with another ATT.

show abstract

Development of depression in patients using androgen deprivation therapy: A systemic review and meta‐analysis

Qazi,

Altaf,

Zafar

et al. 2024

The Prostate

View full text Add to dashboard Cite

BackgroundAndrogen deprivation therapy (ADT) is an effective treatment for advanced prostate cancer (PCa). Multiple studies have highlighted serious consequences this therapy poses to mental health, particularly depression. We aimed to review the incidence and association between ADT in men with PCa and the risk of depression.MethodsWe systematically searched multiple databases, including MEDLINE, Scopus till August 2023 for studies that compared ADT versus control for treating PCa reporting depression as outcome. Meta‐analysis was performed using random‐effects models and results presented as odds ratios (ORs) with 95% confidence interval (CI). Quality assessment of the included studies was conducted using Joanna Briggs Institute critical appraisal checklists.ResultsA total of 38 studies (17 retrospective studies, 16 prospective studies, two cross‐sectional studies and two randomized trials) with 360,650 subjects met the inclusion criteria and were included in this meta‐analysis. The estimated pooled incidence of depression among ADT patients is 209.5 (95% CI = 122.3; 312.2) per 1000 patients. There is statistically significant relationship between ADT treatment and depression (OR = 1.46, 95% CI = 1.28, 1.67; p = 0, I2 = 86.4%). The results remained consistent across various subgroups. No risk of publication bias was detected by funnel plot and Eggers's test (p > 0.05).ConclusionThere is a higher risk of depression for men receiving ADT. Further studies evaluating optimal treatments for depression in men on ADT are warranted

show abstract

Androgen deprivation therapy increases brain ageing

Cited by 14 publications

References 53 publications

Effect of androgen deprivation therapy on cognitive functioning in men with prostate cancer: A systematic review

Effect of androgen deprivation therapy on cognitive functioning in men with prostate cancer: A systematic review

Androgen‐targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer

Development of depression in patients using androgen deprivation therapy: A systemic review and meta‐analysis

Contact Info

Product

Resources

About